title: Comparison of poractant alfa and lyophilized lucinactant in a preterm lamb model of acute respiratory distress.
abstract: BACKGROUND
  A lyophilized formulation of lucinactant has been developed to simplify preparation and dosing. Endotracheal administration of surfactant can be associated with potentially harmful transient hemodynamic changes including decreases in cerebral blood flow and delivery of O2 to the brain. Efficacy and peri-dosing effects of poractant alfa and a lyophilized form of lucinactant were compared in this study.
  
  
  METHODS
  Premature lambs (126-129 d gestation) were delivered by c-section, tracheostomized, ventilated, and instrumented with cerebral laser Doppler flowmetry and tissue PO2 probes. Pulmonary compliance and tidal volumes were monitored continuously and surfactant lung distribution was assessed. Lambs received either poractant alfa or lyophilized lucinactant and were monitored for 3 h after treatment.
  
  
  RESULTS
  Both groups showed significant improvements in arterial pCO2, pH, pulmonary compliance, and tidal volume (all P < 0.01), a similar intra-pulmonary distribution profile, and no significant changes in arterial blood pressure or cerebral blood flow. Administration of poractant alfa was associated with higher mean airway pressures from 75 min post-dosing and transiently decreased heart rate and increased brain tissue PO2 during the first 30 min after treatment.
  
  
  CONCLUSIONS
  In this newborn lamb model of respiratory distress, lyophilized lucinactant results in improved lung function as compared with poractant alfa.
authors.affiliation: Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland.
authors.forename: Jan
authors.initials: J
authors.lastname: Mazela
authors.forename: Allen
authors.initials: A
authors.lastname: Merritt
authors.forename: Michael H
authors.initials: MH
authors.lastname: Terry
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Gregory
authors.forename: Arlin B
authors.initials: AB
authors.lastname: Blood
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001688:Biological Products / Q000378:metabolism / Q000494:pharmacology*; D001784:Blood Gas Analysis; D002626:Chemistry, Pharmaceutical; D004195:Disease Models, Animal; D004338:Drug Combinations; D005233:Fatty Alcohols / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D005612:Freeze Drying; D005865:Gestational Age; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D010715:Phosphatidylglycerols / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D010743:Phospholipids / Q000378:metabolism / Q000494:pharmacology*; D047928:Premature Birth; D011506:Proteins / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D011663:Pulmonary Surfactants / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D020127:Recovery of Function; D012119:Respiration / Q000187:drug effects*; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012129:Respiratory Function Tests; D012756:Sheep; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D001688:Biological Products; D004338:Drug Combinations; D005233:Fatty Alcohols; D010715:Phosphatidylglycerols; D010743:Phospholipids; D011506:Proteins; D011663:Pulmonary Surfactants; C502722:lucinactant; C068291:poractant alfa